NCT05282108View on ClinicalTrials.gov

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Carcemia

Generic Imatinib

DRUG

Glivec

Imatinib

Trial Locations (4)

11796

RECRUITING

National Cancer Institute (NCI), Cairo

Unknown

NOT_YET_RECRUITING

Ain Shams University Hospital, Cairo

RECRUITING

Nasser Institute, Cairo

NOT_YET_RECRUITING

Tanta Oncology Center, Tanta

Sponsors
All Listed Sponsors
lead

Hikma Pharmaceuticals LLC

INDUSTRY